Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
MNPR 
Monopar Therapeutics Inc (MNPR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: MNPR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $62.18
1 Year Target Price $62.18
| 2 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 258.52% | Avg. Invested days 61 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 219.29M USD | Price to earnings Ratio - | 1Y Target Price 62.18 |
Price to earnings Ratio - | 1Y Target Price 62.18 | ||
Volume (30-day avg) 5 | Beta 1.06 | 52 Weeks Range 2.15 - 54.30 | Updated Date 08/15/2025 |
52 Weeks Range 2.15 - 54.30 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.84 |
Earnings Date
Report Date 2025-08-12 | When - | Estimate -0.4833 | Actual -0.35 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -39.12% | Return on Equity (TTM) -59.38% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 166121531 | Price to Sales(TTM) - |
Enterprise Value 166121531 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.42 | Shares Outstanding 6115210 | Shares Floating 2909260 |
Shares Outstanding 6115210 | Shares Floating 2909260 | ||
Percent Insiders 34.25 | Percent Institutions 52.08 |
Upturn AI SWOT
Monopar Therapeutics Inc
Company Overview
History and Background
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics to treat serious diseases. Founded in 2014, Monopar went public in 2020 (MNPR). It focuses on developing innovative treatments for cancer and other diseases.
Core Business Areas
- Cancer Therapeutics Development: Monopar focuses on developing cancer treatments using various methods including synthetic lethality and cell-based therapies.
Leadership and Structure
The leadership team includes Chandler D. Robinson, MD (CEO) and other key executives. The organizational structure consists of research and development, clinical trials, and management teams.
Top Products and Market Share
Key Offerings
- Validive: Validive is an investigational oral solution designed to prevent severe mucositis in patients undergoing chemo-radiotherapy for oropharyngeal cancer. Competitors: There are supportive care products to alleviate symptoms, but no direct competitors for prevention of severe mucositis caused by chemo-radiotherapy.
- MNPR-101: MNPR-101 is a preclinical stage therapeutic antibody targeting urokinase plasminogen activator receptor (uPAR). Competitors: Other companies developing antibody-based therapeutics for cancer, although not specifically targeting uPAR.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and dynamic, driven by innovation and regulatory approvals. Demand for novel cancer therapies continues to grow.
Positioning
Monopar is a clinical-stage company targeting unmet needs in cancer treatment. Its competitive advantage lies in its proprietary therapeutic approaches.
Total Addressable Market (TAM)
The TAM for cancer therapeutics is substantial, estimated in the billions of dollars. Monopar is positioned to capture a portion of this market with successful clinical trials and product approvals.
Upturn SWOT Analysis
Strengths
- Proprietary therapeutic pipeline
- Experienced management team
- Focus on unmet medical needs
- Innovative R&D approach
Weaknesses
- Clinical-stage company with no approved products
- High reliance on clinical trial outcomes
- Limited financial resources
- Small market capitalization
Opportunities
- Successful clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion of therapeutic pipeline
- Acquisition by a larger company
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from larger pharmaceutical companies
- Patent expirations
Competitors and Market Share
Key Competitors
- MRK
- BMY
- PFE
- AZN
Competitive Landscape
Monopar faces stiff competition from larger pharmaceutical companies with greater resources. Its advantage lies in its innovative approaches and focus on unmet needs.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by the progress of its clinical trials and preclinical research.
Future Projections: Future growth is contingent on successful clinical trial outcomes and regulatory approvals. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing Validive into Phase 3 trials and progressing MNPR-101.
Summary
Monopar Therapeutics is a clinical-stage company that is trying to fill unmet medical needs. Its success hinges on the success of its drug candidates in clinical trials, particularly Validive and MNPR-101. The company's lack of revenue and small size make it high risk, although potential drug approvals could significantly increase its stock value. Investors should closely monitor clinical trial results and regulatory milestones. Monopar is a risky investment with a high payout potential if clinical trials prove successful.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings, Analyst reports, Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Monopar Therapeutics Inc
Exchange NASDAQ | Headquaters Wilmette, IL, United States | ||
IPO Launch date 2019-12-19 | Co-Founder, CEO, President & Director Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MSc | ||
Sector Healthcare | Industry Biotechnology | Full time employees 14 | Website https://www.monopartx.com |
Full time employees 14 | Website https://www.monopartx.com | ||
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.